Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Unveils 21 Policy Changes To Increase Transparency With Public

This article was originally published in The Gray Sheet

Executive Summary

FDA may publicly disclose more information on specific devices prior to marketing approval under a May 19 proposal to increase transparency
Advertisement

Related Content

Industry Involvement In Guidance Development Encouraged By FDA Working Group
Regulatory News In Brief
Clinical Investigators' Financial Disclosures Might Become Public – Guidance
FDA Unveils Plan To Boost Transparency To Industry
Exit Interview: FDA's Joshua Sharfstein Reflects On Brief But Busy Tenure
Device Firms Criticize FDA Proposals To Share More Pre-Market Intel
Regulatory News In Brief
Industry Reps Meet With FDA Leadership To Talk Transparency
FDA Aims To Explain Itself Better With New Transparency Task Force
FDA Aims To Explain Itself Better With New Transparency Task Force

Topics

Advertisement
UsernamePublicRestriction

Register

MT028909

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel